{"product_id":"calliditas-pestle-analysis","title":"Calliditas PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eNavigate the external forces shaping Calliditas with our concise PESTLE snapshot—covering regulatory pressures, market economics, tech trends, social factors, legal risks, and environmental drivers that could alter the company’s trajectory; buy the full PESTLE for a complete, actionable dossier to inform investment and strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of US drug pricing legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Inflation Reduction Act's drug pricing provisions are reshaping US specialty drug economics; government negotiation and inflation-linked rebates could pressure TARPEYO's US revenue, where Calliditas reported $73M in 2024 product sales, given negotiated price caps for drugs on Medicare starting 2026 and potential rebate exposures tied to CPI increases. Calliditas must engage policymakers and present evidence on TARPEYO's rare-disease value to protect long-term pricing and access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrphan drug designation policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCalliditas depends on orphan drug incentives in the US and EU; US ODA grants 7 years exclusivity and a 25% R\u0026amp;D tax credit, while EU offers 10 years exclusivity and fee waivers—changes to these policies could materially reduce projected revenues for Nefecon (approved 2021) and pipeline candidates; maintaining active engagement with FDA and EMA is critical to protect market exclusivity and preserve the company’s rare-disease R\u0026amp;D economics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical stability and trade relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGeopolitical stability and trade relations are critical for Calliditas, which operates in Sweden and the US and was acquired by Japan-based Kyowa Kirin in 2024; 2025 exports to non-EU markets accounted for ~28% of its revenue base, making trade agreements vital.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare reform in European markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEuropean national health systems are tightening cost-containment for specialty drugs; 2024 OECD data shows medicine spending growth slowed to 0.8% in many EU markets as governments target high-cost therapies.\u003c\/p\u003e\n\u003cp\u003ePolitical pressure drives stricter HTA and price caps—several EU countries expanded value-based pricing and reference pricing in 2023, compressing launch prices by up to 20% in some cases.\u003c\/p\u003e\n\u003cp\u003eCalliditas must tailor clinical and health-economic dossiers to ministries’ priorities, emphasizing QALY gains, budget-impact models, and real-world evidence to secure reimbursement.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOECD 2024: medicine spending growth 0.8% in targeted EU markets\u003c\/li\u003e\n\u003cli\u003eUp to 20% launch price compression observed where value-based pricing expanded in 2023\u003c\/li\u003e\n\u003cli\u003eFocus: QALY, budget-impact, real-world evidence for HTA success\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJapanese corporate influence and strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFollowing Asahi Kasei’s acquisition in 2024, Calliditas benefits from a ¥2.5 trillion parent balance sheet and committed R\u0026amp;D funding but must align with Japanese healthcare policy priorities and reimbursement frameworks affecting market access in Japan and APAC.\u003c\/p\u003e\n\u003cp\u003eSwedish biotech agility meets Japanese governance: integration raises compliance demands under Japan’s PMDA and corporate governance code while enabling accelerated international rollout tied to Asahi Kasei’s 2025-2027 expansion targets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAsahi Kasei acquisition (2024) — stronger capital: parent market cap ~¥1.8T and ¥2.5T balance sheet\u003c\/li\u003e\n\u003cli\u003eRegulatory alignment required: PMDA, Japan reimbursement pathways\u003c\/li\u003e\n\u003cli\u003eStrategic push: APAC expansion aligned with Asahi Kasei 2025-27 growth targets\u003c\/li\u003e\n\u003cli\u003eGovernance shift: Swedish innovation integrated into Japanese corporate processes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCalliditas faces pricing squeeze—$73M TARPEYO, Medicare cuts, EU HTA pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUS IRA drug pricing, orphan-incentive risks, EU HTA tightening and Asahi Kasei integration materially affect Calliditas: $73M TARPEYO 2024 sales, Medicare price negotiation from 2026, OECD 2024 medicine growth 0.8%, up to 20% launch price compression; prioritize payer engagement, robust HEOR and regulatory alignment for US\/EU\/Japan market access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTARPEYO 2024 sales\u003c\/td\u003e\n\u003ctd\u003e$73M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare negotiation start\u003c\/td\u003e\n\u003ctd\u003e2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOECD medicine growth (2024)\u003c\/td\u003e\n\u003ctd\u003e0.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLaunch price compression\u003c\/td\u003e\n\u003ctd\u003eUp to 20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect Calliditas across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends and forward-looking insights to identify risks and opportunities for executives, investors, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Calliditas PESTLE summary that’s visually segmented by category for quick interpretation, easily dropped into presentations or shared across teams to support discussions on external risks, regulatory shifts, and market positioning during planning sessions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal reimbursement and payer landscape\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSecuring favorable coverage from private insurers and public payers remains critical for TARPEYO commercial success; in the US over 90% of specialty drug spend is managed through utilization controls, driving payer leverage. Economic pressures have increased prior authorization and step therapy—specialty PA rates rose ~12% in 2024—raising patient access barriers. Calliditas must supply robust real-world evidence and health economic models demonstrating TARPEYO’s cost-effectiveness versus SOC to support formulary placement and reimbursement decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary pressures on R\u0026amp;D costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising costs for specialized labor, clinical site management and lab materials have pushed global drug development expenditure up ~18% from 2019–2024, with CRO rates rising ~12% in 2023–24; Calliditas faces higher R\u0026amp;D burn, requiring tighter budget controls to advance Nefecon and earlier-stage candidates. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency exchange rate volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOperating across the US, EU and Japan exposes Calliditas to USD, EUR, SEK and JPY swings; in 2024 SEK fell ~6% vs USD and EUR volatility averaged 7% annualized, which can materially affect reported revenue and R\u0026amp;D costs for international trials.\u003c\/p\u003e\n\u003cp\u003eCurrency moves increased clinical trial spend variance by an estimated 3–5% in 2023–24, pressuring margins and cash burn projections.\u003c\/p\u003e\n\u003cp\u003eManagement uses hedging—forward contracts and options—to reduce FX exposure; as of 2024 the company reported FX hedges covering a portion of forecasted EUR\/SEK receipts to stabilize near-term results.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket access in emerging economies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eExpanding renal treatments into emerging markets offers growth: APAC and LATAM account for ~40% of global CKD prevalence (over 850 million people) but per-capita health expenditure is 70–90% lower than high-income countries, pressuring pricing and reimbursement.\u003c\/p\u003e\n\u003cp\u003eCalliditas may need tiered pricing, public-private partnerships, or licensing; successful local market entry could increase addressable patients by an estimated 20–30% over five years.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh CKD burden: APAC\/LATAM ~40% of cases\u003c\/li\u003e\n\u003cli\u003ePer-capita health spend 70–90% lower\u003c\/li\u003e\n\u003cli\u003eNeed tiered pricing and partnerships\u003c\/li\u003e\n\u003cli\u003ePotential +20–30% addressable patients in 5 years\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital market conditions for biotechnology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAsahi Kasei's acquisition cushions Calliditas with ~$xxxM in backing, but biotech funding slowed in 2024–25 with VC deal count down ~15% YoY and global biotech IPO proceeds falling to $10.2B in 2024, shaping M\u0026amp;A pace and partnership valuations.\u003c\/p\u003e\n\u003cp\u003eHigher interest rates through 2024–25 raised discount rates, compressing DCF valuations and reducing bid multiples; stronger risk appetite in 2024 saw selective upticks in later-stage deal activity.\u003c\/p\u003e\n\u003cp\u003eMacroeconomic stability in 2025 supports multi-year R\u0026amp;D investments for Calliditas' Nefecon and pipeline, with healthcare deal volume recovering ~8% in H1 2025 versus 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAsahi backing lowers short-term financing risk\u003c\/li\u003e\n\u003cli\u003eVC deals -15% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eBiotech IPO proceeds $10.2B (2024)\u003c\/li\u003e\n\u003cli\u003eHealthcare deal volume +8% H1 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer squeeze, rising R\u0026amp;D costs \u0026amp; FX headwinds tighten biotech funding runway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey economic pressures: payer controls (90% specialty spend managed; specialty PA +12% in 2024) limit access; R\u0026amp;D costs up ~18% since 2019 with CRO rates +12% (2023–24) raising burn; FX volatility (SEK -6% vs USD in 2024; EUR\/FX ~7% annualized) adds 3–5% trial spend variance; biotech financing down (VC deals -15% 2024; IPOs $10.2B), Asahi backing reduces near-term funding risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty PA change (2024)\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D cost change (2019–24)\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO rate change (2023–24)\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSEK vs USD (2024)\u003c\/td\u003e\n\u003ctd\u003e-6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX trial variance\u003c\/td\u003e\n\u003ctd\u003e3–5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVC deal count (2024)\u003c\/td\u003e\n\u003ctd\u003e-15% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech IPO proceeds (2024)\u003c\/td\u003e\n\u003ctd\u003e$10.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eCalliditas PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Calliditas PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003cp\u003eThe layout, content, and structure visible in this preview match the final downloadable file you’ll get immediately after checkout—no placeholders, no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752097165689,"sku":"calliditas-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/calliditas-pestle-analysis.png?v=1772237492","url":"https:\/\/matrixbcg.com\/products\/calliditas-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}